Evaluation of variability of silymarin complex in Silybi mariani fructus harvested during two production years

European Pharmaceutical Journal Pub Date : 2021-01-01 DOI:10.2478/afpuc-2020-0023

M. Habán, D. Zvercová, M. Adamjaková

{"title":"Evaluation of variability of silymarin complex in Silybi mariani fructus harvested during two production years","authors":"M. Habán, D. Zvercová, M. Adamjaková","doi":"10.2478/afpuc-2020-0023","DOIUrl":null,"url":null,"abstract":"Abstract Milk thistle [Silybum marianum (L.) Gaertn.], a member of Asteraceae family, is one of the most cultivated medicinal plants widespread throughout the world. The pharmacological drug is a ripe fruit without pappus – Silybi mariani fructus – containing flavonolignans and generating silymarin complex. In folk medicine, it is used for the treatment of liver disorders, kidney problems, rheumatism as well as gastronomic disturbances, cardiac and neurotic disorders, and fever. The components of silymarin complex are useful in cancer prevention and treatment. The aim of the study was to determine the amount of silymarin complex contained in the fruit of the harvest of two consecutive years and how much they differ from one another. Representative samples of fruit were collected in 2015 and 2016 and distributed by a company Agrofos (Slovakia). Regarding the analytical method, we used a high-performance liquid chromatography (HPLC); the method was approved by the European Pharmacopoeia 10. The statistical significance was on the level P < 0.05. The total content of silymarin complex was 15.28 ± 0.06 g.kg−1 (in 2015) and 16.65 ± 0.09 g.kg−1 (in 2016). In both studied years, the highest representation of silybin B was observed (7.04 ± 0.07 g.kg−1 versus 5.92 ± 0.08 g.kg−1). The differences between the individual fractions of the silymarin complex were statistically significant. There was also a significant difference of 9% in the total silymarin content between 2015 and 2016. In conclusion, we can state that both samples of Silybi mariani fructus meet the requirements of the European Pharmacopoeia.","PeriodicalId":12070,"journal":{"name":"European Pharmaceutical Journal","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Pharmaceutical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2478/afpuc-2020-0023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Abstract Milk thistle [Silybum marianum (L.) Gaertn.], a member of Asteraceae family, is one of the most cultivated medicinal plants widespread throughout the world. The pharmacological drug is a ripe fruit without pappus – Silybi mariani fructus – containing flavonolignans and generating silymarin complex. In folk medicine, it is used for the treatment of liver disorders, kidney problems, rheumatism as well as gastronomic disturbances, cardiac and neurotic disorders, and fever. The components of silymarin complex are useful in cancer prevention and treatment. The aim of the study was to determine the amount of silymarin complex contained in the fruit of the harvest of two consecutive years and how much they differ from one another. Representative samples of fruit were collected in 2015 and 2016 and distributed by a company Agrofos (Slovakia). Regarding the analytical method, we used a high-performance liquid chromatography (HPLC); the method was approved by the European Pharmacopoeia 10. The statistical significance was on the level P < 0.05. The total content of silymarin complex was 15.28 ± 0.06 g.kg−1 (in 2015) and 16.65 ± 0.09 g.kg−1 (in 2016). In both studied years, the highest representation of silybin B was observed (7.04 ± 0.07 g.kg−1 versus 5.92 ± 0.08 g.kg−1). The differences between the individual fractions of the silymarin complex were statistically significant. There was also a significant difference of 9% in the total silymarin content between 2015 and 2016. In conclusion, we can state that both samples of Silybi mariani fructus meet the requirements of the European Pharmacopoeia.

查看原文本刊更多论文

两个生产年份水飞蓟果实水飞蓟素复合物变异性的评价

摘要乳蓟（Silybum marianum（L.）Gaertn.）是菊科的一员，是世界上种植最广泛的药用植物之一。该药物是一种不含pappus的成熟水果——水飞蓟果——含有黄酮类化合物并产生水飞蓟素复合物。在民间医学中，它被用于治疗肝脏疾病、肾脏问题、风湿病以及胃肠道疾病、心脏和神经系统疾病以及发烧。水飞蓟素复合物的组分可用于癌症的预防和治疗。该研究的目的是确定连续两年收获的果实中所含水飞蓟素复合物的含量，以及它们之间的差异。2015年和2016年采集了具有代表性的水果样本，并由Agrofos（斯洛伐克）公司分发。关于分析方法，我们使用了高效液相色谱法；该方法被欧洲药典10批准。差异有统计学意义（P＜0.05）。水飞蓟素复合物的总含量为15.28±0.06 g.kg-1（2015年）和16.65±0.09 g.kg-1（2016年）。在两个研究年份中，观察到水飞蓟宾B的最高代表性（7.04±0.07 g.kg−1对5.92±0.08 g.kg−2）。水飞蓟素复合物的各个部分之间的差异具有统计学意义。2015年至2016年间，水飞蓟素总含量也存在9%的显著差异。总之，我们可以声明水飞蓟果的两个样品都符合欧洲药典的要求。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Pharmaceutical Journal Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)

CiteScore

0.60

自引率

0.00%

发文量

期刊介绍： European Pharmaceutical Journal publishes only original articles not previously published and articles that are not being considered or have not been submitted for publication elsewhere. If parts of the results have been published as conference abstract or elsewhere, it should be stated in references. The ethical standards of the Helsinki-Tokio Declaration should be kept. This should be mentioned in the Methods of manuscript. Reviews are published only on request. Authors, whose submitted research work was performed with the support of a company, should indicate this in Conflict of Interest.